Advertisement

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

Shaji K. Kumar, Betsy LaPlant, Wee Joo Chng, Jeffrey Zonder, Natalie Callander, Rafael Fonseca, Briant Fruth, Vivek Roy, Charles Erlichman and A. Keith Stewart for the Mayo Phase 2 Consortium

Article Information

Citation 
vol. 125 no. 3 443-448
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted May 6, 2014
  • Accepted October 29, 2014
  • Published online January 15, 2015.


Contributors 
  • Shaji K. Kumar, 1Division of Hematology and
  • Betsy LaPlant, 2Department of Biostatistics, Mayo Clinic, Rochester, MN;
  • Wee Joo Chng, 3Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore;
  • Jeffrey Zonder, 4Karmanos Cancer Center, Detroit, MI;
  • Natalie Callander, 5Section of Hematology and Bone Marrow Transplant, University of Wisconsin, Madison, WI;
  • Rafael Fonseca, 6Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ;
  • Briant Fruth, 2Department of Biostatistics, Mayo Clinic, Rochester, MN;
  • Vivek Roy, 7Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; and
  • Charles Erlichman, 8Division of Medical Oncology, Mayo Clinic, Rochester, MN
  • A. Keith Stewart, 6Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output